KCN1

WARNING: This product is for research use only, not for human or veterinary use.

Description:KCN1, a novel synthetic sulfonamide, is a HIF pathway inhibitor with potential anticancer activity in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. KCN1 specifically inhibited HIF reporter gene activity in several glioma cell lines at the nanomolar level. KCN1 also downregulated transcription of endogenous HIF-1 target genes, such as VEGF, Glut-1, and carbonic anhydrase 9, in a hypoxia-responsive element (HRE)-dependent manner. KCN1 potently inhibited the growth of subcutaneous malignant glioma tumor xenografts with minimal adverse effects on the host.

Price and Availability

KCN1 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure

Theoretical Analysis

MedKoo Cat#: 401515Name: KCN1CAS#: 927823-01-6Chemical Formula: C26H27NO5SExact Mass: 465.16099Molecular Weight: 465.56Elemental Analysis: C, 67.08; H, 5.85; N, 3.01; O, 17.18; S, 6.89

Synonym:KCN1; KCN-1; KCN 1.

IUPAC/Chemical Name:3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulfonamide

InChi Key:IPZJNJPAVPZHJM-UHFFFAOYSA-N

InChi Code:InChI=1S/C26H27NO5S/c1-26(2)15-14-20-16-19(10-12-23(20)32-26)18-27(21-8-6-5-7-9-21)33(28,29)22-11-13-24(30-3)25(17-22)31-4/h5-17H,18H2,1-4H3

SMILES Code:O=S(C1=CC=C(OC)C(OC)=C1)(N(CC2=CC(C=CC(C)(C)O3)=C3C=C2)C4=CC=CC=C4)=O

Technical Data

Additional Information

   The following data was from PLoS One . 2012;7(9):e44883. doi: 10.1371/journal.pone.0044883. Epub 2012 Sep 13.        Figure 1. In vitro anticancer activities of KCN1 against pancreatic cancer cells.  (B) Cell growth inhibitory activity of KCN1 in human pancreatic cancer cells. Cells were exposed to various concentrations of KCN1 for 72 h, followed by an MTT assay. ( Source: PLoS One . 2012;7(9):e44883. doi: 10.1371/journal.pone.0044883. Epub 2012 Sep 13. )Figure 1. In vitro anticancer activities of KCN1 against pancreatic cancer cells.  (B) Cell growth inhibitory activity of KCN1 in human pancreatic cancer cells. Cells were exposed to various concentrations of KCN1 for 72 h, followed by an MTT assay. ()                

References

1: Wang W, Ao L, Rayburn ER, Xu H, Zhang X, Zhang X,Nag SA, Wu X, Wang MH, Wang H, Van Meir EG, Zhang R. KCN1, a novelsynthetic sulfonamide anticancer agent: in vitro and in vivoanti-pancreatic cancer activities and preclinical pharmacology. PLoSOne. 2012;7(9):e44883. doi: 10.1371/journal.pone.0044883. Epub 2012 Sep13. PubMed PMID: 23028659; PubMed Central PMCID: PMC3441526.

2: Yin S, Kaluz S, Devi NS, Jabbar AA, de Noronha RG, Mun J, Zhang Z,Boreddy PR, Wang W, Wang Z, Abbruscato T, Chen Z, Olson JJ, Zhang R,Goodman MM, Nicolaou KC, Van Meir EG. Arylsulfonamide KCN1 Inhibits InVivo Glioma Growth and Interferes with HIF Signaling by DisruptingHIF-1α Interaction with Cofactors p300/CBP. Clin Cancer Res. 2012 Nov21. [Epub ahead of print] PubMed PMID: 22923450; PubMed Central PMCID:PMC3518680.